Oral Oncology Reports,
Journal Year:
2024,
Volume and Issue:
10, P. 100348 - 100348
Published: April 8, 2024
•
Pott's
disease,
is
a
severe
form
of
tuberculosis
that
affects
the
spine.
Spinal
typically
begins
with
infection
vertebral
bodies
or
intervertebral
discs
by
Mycobacterium
bacteria.
Treatment
spinal
involves
combination
anti-tuberculosis
medications.
TB
infectious,
however
inflammation
and
tissue
damage
may
increase
risk
bone
tumours.
MRI,
CT,
X-rays
can
assess
TB,
presented
report
showcase
recent
advancement
diagnostic
methods
used
for
MTB
infection.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 1213 - 1262
Published: Jan. 1, 2025
Liposomal
nanomedicines
have
emerged
as
a
pivotal
approach
for
the
treatment
of
various
diseases,
notably
cancer
and
infectious
diseases.
This
manuscript
provides
an
in-depth
review
recent
advancements
in
liposomal
formulations,
highlighting
their
composition,
targeted
delivery
strategies,
mechanisms
action.
We
explore
evolution
products
currently
clinical
trials,
emphasizing
potential
addressing
diverse
medical
challenges.
The
integration
immunotherapeutic
agents
within
liposomes
marks
paradigm
shift,
enabling
design
'immuno-modulatory
hubs'
capable
orchestrating
precise
immune
responses
while
facilitating
theranostic
applications.
COVID-19
pandemic
has
accelerated
research
liposomal-based
vaccines
antiviral
therapies,
underscoring
need
improved
to
overcome
challenges
like
rapid
clearance
organ
toxicity.
Furthermore,
we
discuss
"smart"
liposomes,
which
can
respond
specific
disease
microenvironments,
enhancing
efficacy
precision.
artificial
intelligence
machine
learning
optimizing
designs
promises
revolutionize
personalized
medicine,
paving
way
innovative
strategies
detection
therapeutic
interventions.
comprehensive
underscores
significance
ongoing
technologies,
with
implications
future
applications
enhanced
patient
outcomes.
Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(10), P. 1360 - 1360
Published: Sept. 26, 2023
The
World
Health
Organization
identifies
tuberculosis
(TB),
caused
by
Mycobacterium
tuberculosis,
as
a
leading
infectious
killer.
Although
conventional
treatments
for
TB
exist,
they
come
with
challenges
such
heavy
pill
regimen,
prolonged
treatment
duration,
and
strict
schedule,
to
multidrug-resistant
(MDR)
extensively
drug-resistant
(XDR)
strains.
rise
of
MDR
strains
endangers
future
control.
Despite
these
concerns,
the
hunt
an
efficient
continues.
One
breakthrough
has
been
use
nanotechnology
in
medicines,
presenting
novel
approach
treatment.
Nanocarriers,
lipid
nanoparticles,
nanosuspensions,
liposomes,
polymeric
micelles,
facilitate
targeted
delivery
anti-TB
drugs.
benefits
nanocarriers
include
reduced
drug
doses,
fewer
side
effects,
improved
solubility,
better
bioavailability,
patient
compliance,
speeding
up
recovery.
Additionally,
can
be
made
even
more
linking
them
ligands
mannose
or
hyaluronic
acid.
This
review
explores
innovative
treatments,
including
studies
on
containing
drugs
related
patents.
Journal of Preventive Diagnostic and Treatment Strategies in Medicine,
Journal Year:
2024,
Volume and Issue:
3(2), P. 71 - 75
Published: April 1, 2024
Abstract
In
the
current
scenario,
rise
of
multidrug-resistant
strains
Mycobacterium
tuberculosis
(MTB)
poses
a
worldwide
challenge.
MTB
is
an
acid-fast
bacillus
that
shows
varying
degrees
mutation
among
different
and
especially
found
to
be
resistant
two
major
drugs
(antibiotics):
rifampicin
isoniazid.
Hence,
early
diagnosis
multidrug
resistance
(MDR)
critical
initiate
effective
therapy
against
protect
community
spread
MDR
strains.
Till
now,
mainly,
diagnostic
methods
have
been
developed
for
determining
pathogen
drug
susceptibility/resistance
MTB,
namely,
phenotypic
analysis
using
microscopic
like
bacilli
antibiotic
culture
along
with
Ziehl–Neelsen
staining
molecular
such
as
real-time
qualitative/quantitative
polymerase
chain
reaction
(RT-qPCR).
The
key
advantages
RT-qPCR
over
include
rapid
detection
specificity
diagnosis.
Microscopic
on
other
hand
require
long
culturing
times
sometimes
lead
false-negative
results
would
result
in
improper
treatment
outcomes
and/or
transmission
strain.
contrast,
false-positive
can
also
occur
due
genetic
variations
presence
mixed
population
susceptible/resistant
clinical
samples,
which
may
mask
susceptible
genes.
Consequently,
optimal
approach
will
likely
involve
both
identify
facilitate
appropriate
management
MDR-MTB
by
reducing
its
infection
human
population.
Therefore,
should
accompanied
improve
sensitivity
Microorganisms,
Journal Year:
2025,
Volume and Issue:
13(4), P. 722 - 722
Published: March 24, 2025
Multidrug-resistant
tuberculosis
(MDR-TB)
is
a
significant
public
health
challenge
globally,
exacerbated
by
the
limited
efficacy
of
existing
therapeutic
approaches,
prolonged
treatment
duration,
and
severe
side
effects.
As
drug
resistance
continues
to
emerge,
innovative
delivery
systems
strategies
are
critical
combating
this
crisis.
This
review
highlights
molecular
mechanisms
underlying
drugs
in
Mycobacterium
tuberculosis,
such
as
genetic
mutation,
efflux
pump
activity,
biofilm
formation,
contributing
persistence
difficulty
eradicating
MDR-TB.
Current
options,
including
second-line
drugs,
offer
effectiveness,
prompting
need
for
innovation
advanced
therapies
systems.
The
progression
discovery
has
resulted
approval
therapeutics,
bedaquiline
delamanid,
amongst
other
promising
candidates
under
investigation.
However,
overcoming
limitations
traditional
remains
challenge.
Nanotechnology
emerged
solution,
with
nanoparticle-based
offering
improved
bioavailability
targeted
controlled
release
delivery,
particularly
pulmonary
targeting
intracellular
macrophages.
Furthermore,
development
inhalable
formulations
potential
nanomedicines
bypass
presents
novel
approach
enhancing
efficacy.
Moreover,
adjunctive
therapies,
immune
modulation
host-directed
being
explored
improve
outcomes.
Immunotherapies,
cytokine
TB
vaccines,
complementary
use
antibiotics
Personalized
medicine
leveraging
genomic
profiling
both
pathogen
host,
promise
optimizing
regimens
minimizing
resistance.
underscores
importance
multidisciplinary
combining
discovery,
system
development,
address
complexities
treating
Continued
innovation,
global
collaboration,
diagnostics
essential
developing
practical,
accessible,
affordable
treatments
